What is the address of REMEDUS PHARMA?

The registered office of REMEDUS PHARMA is located at Brussegemsesteenweg 39, 1861 Meise.

Is REMEDUS PHARMA still active?

Yes. According to the CBE (29 October 2026) REMEDUS PHARMA is active, legal situation “Normale toestand”, started on 5 June 2003.

Is REMEDUS PHARMA registered on Peppol?

Yes, REMEDUS PHARMA is registered on the Peppol network with ID 0208:0480727149.

What is the enterprise number of REMEDUS PHARMA?

The enterprise number of REMEDUS PHARMA is BE0480727149.

When was REMEDUS PHARMA founded?

REMEDUS PHARMA was founded on 5 June 2003.

Who are the directors of REMEDUS PHARMA?

According to the 2024 annual accounts, the directors of REMEDUS PHARMA are: Fabienne Schoonbaert, Jo Ravelingien.

Is REMEDUS PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 5 June 2003; 4 annual accounts filed, latest fiscal year 2024; 2 directors known from the annual account.

How much profit did REMEDUS PHARMA make in 2024?

REMEDUS PHARMA recorded a loss after taxes of € 123,371 in financial year 2024.

What is the revenue of REMEDUS PHARMA?

As a small company, REMEDUS PHARMA is not required to publish revenue in its annual accounts. In financial year 2024, its added value was € 30,695.

How many employees does REMEDUS PHARMA have?

According to the 2024 annual accounts, REMEDUS PHARMA has 0 full-time equivalents (FTE).

REMEDUS PHARMA (Private Limited) - Meise - BE0480727149

Q: What does REMEDUS PHARMA do?

REMEDUS PHARMA is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Private Limited, started on 5 June 2003, 1 establishment.

Dossier REMEDUS PHARMA, printed on 29 October 2026 from databakkes.be/en/0480727149/remedus-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 1 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2023 and 2024.
Tight liquidity NBB

Cash and receivables cover 2 % of short-term debt in 2024; threshold 65 %.

Financials

Financial year 2024

REMEDUS PHARMA from Meise, company number BE0480727149, closed financial year 2024 with a result of € -123,371 after tax. For that financial year REMEDUS PHARMA recorded a gross margin of € 30,695 and equity of € -53,714. Compared with financial year 2023, the result moved from € -245,266 to € -123,371. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 30, 2025.

What it is worth Caution

€ -53,714

▼ € 123,371 vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -123,371

▲ 50 % less loss than in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 46,053

▲ € 42,813 vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -167,914.

People and assets in 2024

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 65,118

▲ 280% vs 2023

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt

€ 500,000

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 3,767

▼ 81% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 21,739

▼ 7% vs 2023

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Gross margin	€ 181,767 Gross margin 2021: € 181,767 First fiscal year in the series	€ 76,455 Gross margin 2022: € 76,455 ▼ 58% vs 2021 (€ 181,767) Unfavourable step	€ -32,403 Gross margin 2023: € -32,403 ▼ € 108,858 vs 2022 (€ 76,455) Unfavourable step	€ 30,695 Gross margin 2024: € 30,695 ▲ € 63,098 vs 2023 (€ -32,403) Favourable step	▲ € 63,098
Profit after taxes	€ 62,295 Profit after taxes 2021: € 62,295 First fiscal year in the series	€ -60,458 Profit after taxes 2022: € -60,458 ▼ € 122,753 vs 2021 (€ 62,295) Unfavourable step	€ -245,266 Profit after taxes 2023: € -245,266 ▼ € 184,808 vs 2022 (€ -60,458) Unfavourable step	€ -123,371 Profit after taxes 2024: € -123,371 ▲ € 121,895 vs 2023 (€ -245,266) Favourable step	▲ € 121,895
Equity	€ 375,381 Equity 2021: € 375,381 First fiscal year in the series	€ 314,923 Equity 2022: € 314,923 ▼ 16% vs 2021 (€ 375,381) Unfavourable step	€ 69,657 Equity 2023: € 69,657 ▼ 78% vs 2022 (€ 314,923) Unfavourable step	€ -53,714 Equity 2024: € -53,714 ▼ € 123,371 vs 2023 (€ 69,657) Unfavourable step	▼ € 123,371
Total debts	€ 502,329 Total debts 2021: € 502,329 First fiscal year in the series	€ 1,521,891 Total debts 2022: € 1,521,891 ▲ 203% vs 2021 (€ 502,329) Unfavourable step	€ 3,001,601 Total debts 2023: € 3,001,601 ▲ 97% vs 2022 (€ 1,521,891) Unfavourable step	€ 3,326,867 Total debts 2024: € 3,326,867 ▲ 11% vs 2023 (€ 3,001,601) Unfavourable step	▲ 11%
Cash	€ 16,759 Cash 2021: € 16,759 First fiscal year in the series	€ 258,317 Cash 2022: € 258,317 ▲ € 241,559 vs 2021 (€ 16,759) Favourable step	€ 3,240 Cash 2023: € 3,240 ▼ 99% vs 2022 (€ 258,317) Unfavourable step	€ 46,053 Cash 2024: € 46,053 ▲ € 42,813 vs 2023 (€ 3,240) Favourable step	▲ € 42,813
Land & buildings	€ 499,946 Land & buildings 2021: € 499,946 First fiscal year in the series	€ 1,231,709 Land & buildings 2022: € 1,231,709 ▲ 146% vs 2021 (€ 499,946) Unchanged	€ 1,104,518 Land & buildings 2023: € 1,104,518 ▼ 10% vs 2022 (€ 1,231,709) Unchanged	€ 2,899,512 Land & buildings 2024: € 2,899,512 ▲ 163% vs 2023 (€ 1,104,518) Unchanged	▲ 163%
Retained profit	€ 261,181 Retained profit 2021: € 261,181 First fiscal year in the series	€ 200,723 Retained profit 2022: € 200,723 ▼ 23% vs 2021 (€ 261,181) Unfavourable step	€ -44,543 Retained profit 2023: € -44,543 ▼ € 245,266 vs 2022 (€ 200,723) Unfavourable step	€ -167,914 Retained profit 2024: € -167,914 ▼ € 123,371 vs 2023 (€ -44,543) Unfavourable step	▼ € 123,371
Bank debt	€ 493,333 Bank debt 2021: € 493,333 First fiscal year in the series	€ 500,000 Bank debt 2022: € 500,000 ▲ 1% vs 2021 (€ 493,333) Unfavourable step	€ 500,000 Bank debt 2023: € 500,000 Unchanged (€ 500,000) Unchanged	€ 500,000 Bank debt 2024: € 500,000 Unchanged (€ 500,000) Unchanged
Balance sheet total	€ 877,710 Balance sheet total 2021: € 877,710 First fiscal year in the series	€ 1,836,814 Balance sheet total 2022: € 1,836,814 ▲ 109% vs 2021 (€ 877,710) Unchanged	€ 3,071,258 Balance sheet total 2023: € 3,071,258 ▲ 67% vs 2022 (€ 1,836,814) Unchanged	€ 3,273,153 Balance sheet total 2024: € 3,273,153 ▲ 7% vs 2023 (€ 3,071,258) Unchanged	▲ 7%

Key figures of REMEDUS PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to REMEDUS PHARMA?

What happened at REMEDUS PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 30, 2025 New annual accounts for financial year 2024: loss of € 123,371. filed late Source: NBB ↗
2005 Fabienne Schoonbaert became a director. NBB
2005 Jo Ravelingien became a director. NBB
Jun 5, 2003 New establishment in Meise. KBO
Jun 5, 2003 Start of the company according to the CBE. KBO

In short

From € 62,295 profit in 2021 to € 123,371 loss in 2024.

Paid € 722 in corporate taxes since 2021.

Best year ever: 2021, with € 62,295 profit.

Original PDFs at the National Bank ↗

Management

Fabienne Schoonbaert Jo Ravelingien

REMEDUS PHARMA

Remecare

Behind REMEDUS PHARMA are Fabienne Schoonbaert and Jo Ravelingien. Jo Ravelingien is also behind Remecare.

Directors

According to the 2024 annual accounts

Fabienne Schoonbaert

Director

since 2005

Jo Ravelingien

Director

Also active at: Remecare

since 2005

Establishments

Establishment units

Physical locations of this company

Registered office

Brussegemsesteenweg 39

1861 Meise

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

Hageput

€ -506 gross margin · 2025

REMEDIA

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0480.727.149

VAT number

BE 0480.727.149

Registered office

Brussegemsesteenweg 39, 1861 Meise

Names & denominations

REMEDUS PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

5 June 2003

Peppol

Active · Active since 27 Mar 2026

Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsvoering en beheer

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

View on CBE Public ↗ Annual accounts (NBB) ↗

REMEDUS PHARMA

Warning lights

Financials

What happened to REMEDUS PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions